FDA today approved a new indication for the previously FDA-approved drug, Zerbaxa (ceftolozane and tazobactam) for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP) in patients 18 years and older.
FDA approves new treatment for hospital-acquired and ventilator-associated bacterial pneumonia
More from FDA News AlertsMore posts in FDA News Alerts »
- Coronavirus (COVID-19) Update: June 22, 2021
- Prairie Wolf Spirits, Inc. Issues Voluntary Nationwide Recall of Prairie Wolf Distillery Hand Sanitizer Packed in 16.9 Oz. and 20 Oz Bottles Because They Resemble Drink Containers
- Sanit Technologies Adds Label Clarification to Existing Voluntary Hand Sanitizer Recall
- FDA Approves First Oral Blood Thinning Medication for Children